Canaccord trims target for Viking Therapeutics stock

Published on 10/27/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking starts two oral Phase 3 studies on October 14, 2026 with 560 adults each. Canaccord cut its target to USD 106 for Viking Therapeutics stock.

Analyst and trial milestones

Canaccord lowered its target from USD 114.00 to USD 106.00 on October 20, 2026.
Viking began two oral Phase 3 studies on October 14, 2026, with 560 adults planned for each trial.
Viking Therapeutics stock traded at EUR 21.50 at 2:32 p.m. CET at Lang & Schwarz on October 27, 2026.

VKTX, US92686J1060, Illustration mit AI erstellt.

Canaccord cut Viking Therapeutics' price target from USD 114.00 to USD 106.00 in an October 20, 2026 note, while Viking Therapeutics stock was trading at EUR 21.50 at Lang & Schwarz on October 27, 2026 at 2:32 p.m. CET. The analyst retained a Buy rating, according to MarketBeat.

Why the target changed

The cut reduced the target by USD 8.00, or 7.02 percent, from the previous USD 114.00 level. MarketBeat said Canaccord was adjusting its model for changing obesity-drug pricing, while maintaining its Buy view on Viking's clinical program.

The wider analyst picture remains constructive but dispersed. MarketBeat reported a Moderate Buy consensus and an average target of USD 98.90 on October 20, 2026, based on 14 research firms. The spread between Canaccord's USD 106.00 target and the average shows how strongly valuation depends on clinical execution.

What does oral testing mean?

Viking started its oral VK2735 Phase 3 SUNRISE program on October 14, 2026. The two studies plan to enroll 560 adults each, according to Yahoo Finance. The program tests whether an oral formulation can extend Viking's obesity strategy beyond its injectable candidates.

That trial launch followed maintenance data reported on September 22, 2026, when patients retained 90 percent to 97 percent of prior weight loss after switching to less frequent dosing. Viking also completed a USD 500.00 million stock and convertible-note offering on September 28, 2026, giving the company additional funding for its expanding clinical program.

Dates set the next test

Viking Therapeutics announced on October 21, 2026 that it will release third-quarter results after the market close on October 28, 2026. The conference call is scheduled for 4:30 p.m. ET that day, and the replay remains accessible until November 4, 2026.

Stock stays tied to clinical delivery

For investors, the next valuation test combines the oral Phase 3 launch, maintenance results and spending plans. The stock's EUR 21.50 Lang & Schwarz indication sits against a USD 106.00 analyst target, but the currencies are different and do not support a direct price-distance calculation.

Viking Therapeutics was trading at EUR 21.50 at Lang & Schwarz on October 27, 2026 at 2:32 p.m. CET. The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.